NASDAQ:VYGR - Voyager Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.18 -0.15 (-0.78 %) (As of 04/18/2019 04:00 PM ET)Previous Close$19.33Today's Range$18.73 - $19.8152-Week Range$7.76 - $24.24Volume329,600 shsAverage Volume542,644 shsMarket Capitalization$625.59 millionP/E RatioN/ADividend YieldN/ABeta2.83 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreement with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as has collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive VYGR News and Ratings via Email Sign-up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR Previous Symbol CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone857-259-5340Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.62 million Price / Sales82.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book13.41Profitability EPS (Most Recent Fiscal Year)($2.75) Net Income$-88,290,000.00 Net Margins-1,158.79% Return on Equity-120.82% Return on Assets-42.87%Miscellaneous Employees123 Outstanding Shares32,617,000Market Cap$625.59 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics Inc (NASDAQ:VYGR) released its quarterly earnings results on Tuesday, February, 26th. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.04. The firm had revenue of $2.01 million for the quarter, compared to analysts' expectations of $2.90 million. Voyager Therapeutics had a negative net margin of 1,158.79% and a negative return on equity of 120.82%. View Voyager Therapeutics' Earnings History. When is Voyager Therapeutics' next earnings date? Voyager Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Voyager Therapeutics. What price target have analysts set for VYGR? 9 Wall Street analysts have issued 1-year price objectives for Voyager Therapeutics' stock. Their forecasts range from $13.00 to $31.00. On average, they expect Voyager Therapeutics' share price to reach $25.00 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View Analyst Price Targets for Voyager Therapeutics. What is the consensus analysts' recommendation for Voyager Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Voyager Therapeutics. What are Wall Street analysts saying about Voyager Therapeutics stock? Here are some recent quotes from research analysts about Voyager Therapeutics stock: 1. According to Zacks Investment Research, "Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (3/2/2019) 2. HC Wainwright analysts commented, "Our $21 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY- AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.47, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (1/15/2019) Has Voyager Therapeutics been receiving favorable news coverage? Media stories about VYGR stock have trended positive on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Voyager Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. Who are some of Voyager Therapeutics' key competitors? Some companies that are related to Voyager Therapeutics include Denali Therapeutics (DNLI), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA) and Editas Medicine (EDIT). What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include TFI International (TFII), Micron Technology (MU), TG Therapeutics (TGTX), Applied Optoelectronics (AAOI), Cara Therapeutics (CARA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP) and Sangamo Therapeutics (SGMO). Who are Voyager Therapeutics' key executives? Voyager Therapeutics' management team includes the folowing people: Mr. Matthew P. Ottmer, Chief Operating Officer (Age 48)Dr. Steven M. Paul, Exec. Science Advisor & Director (Age 68)Mr. G. Andre Turenne, CEO, Pres & DirectorDr. Krystof Bankiewicz M.D., Ph.D., FounderDr. Guangping Gao Ph.D., Founder Who are Voyager Therapeutics' major shareholders? Voyager Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Nisa Investment Advisors LLC (0.03%). Company insiders that own Voyager Therapeutics stock include Bernard Ravina, Dinah PhD Sah, Glenn Pierce, James A Geraghty, Jane Henderson and Neurocrine Biosciences Inc. View Institutional Ownership Trends for Voyager Therapeutics. Which major investors are selling Voyager Therapeutics stock? VYGR stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Voyager Therapeutics. How do I buy shares of Voyager Therapeutics? Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $19.18. How big of a company is Voyager Therapeutics? Voyager Therapeutics has a market capitalization of $625.59 million and generates $7.62 million in revenue each year. The company earns $-88,290,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis. Voyager Therapeutics employs 123 workers across the globe. What is Voyager Therapeutics' official website? The official website for Voyager Therapeutics is http://www.voyagertherapeutics.com. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-5340 or via email at [email protected] MarketBeat Community Rating for Voyager Therapeutics (NASDAQ VYGR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 275 (Vote Outperform)Underperform Votes: 225 (Vote Underperform)Total Votes: 500MarketBeat's community ratings are surveys of what our community members think about Voyager Therapeutics and other stocks. Vote "Outperform" if you believe VYGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VYGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?